Dana V. Rizk

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy

Fernando C. Fervenza, Gerald B. Appel, Sean J. Barbour et al. · New England Journal of Medicine · 2019 · 554 citations · Full text

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 205 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Dietary Patterns and Risk of Death and Progression to ESRD in Individuals With CKD: A Cohort Study

Orlando M. Gutiérrez, Paul Muntner, Dana V. Rizk et al. · American Journal of Kidney Diseases · 2014 · 155 citations · Full text

Nutrition, Dietary Patterns, Urology +9